197 results about "Betalactam antibiotics" patented technology

A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin β-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

The present invention relates to eukaryotic cells which have the ability to convert L-arabinose into D-xylulose 5-phosphate. The cells have acquired this ability by transformation with nucleotide sequences coding for an arabinose isomerase, a ribulokinase, and a ribulose-5-P-4-epimerase from a bacterium that belongs to a Clavibacter, Arthrobacter or Gramella genus. The cell preferably is a yeast or a filamentous fungus, more preferably a yeast is capable of anaerobic alcoholic fermentation. The may further comprise one or more genetic modifications that increase the flux of the pentose phosphate pathway, reduce unspecific aldose reductase activity, confer to the cell the ability to directly isomerise xylose into xylulose, increase the specific xylulose kinase activity, increase transport of at least one of xylose and arabinose into the host cell, decrease sensitivity to catabolite repression, increase tolerance to ethanol, osmolarity or organic acids; and/or reduce production of by-products. The cell preferably is a cell that has the ability to produce a fermentation product such as ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, -lactam antibiotics and cephalosporins. The invention further relates to processes for producing these fermentation products wherein a cell of the invention is used to ferment arabinose into the fermentation products.

The invention discloses a method, a special kit and test paper strips for detecting beta-lactam antibiotics based on penicillin-binding protein. The receptor kit used for detecting beta-lactam antibiotics comprises: protein represented by SEQ ID NO: 1, enzyme labeled ampicillin and a standard substance solution, wherein the standard substance is penicillin G. The kit and colloidal gold test paper strips provided by the invention have advantages of high sensitivity, high accuracy, high precision, low cost, simple operation, short detection period, simple storage, and long shelf-life. The kit and colloidal gold test paper strips are suitable for various work units. With the kit and colloidal gold test paper strips, simultaneous and rapid detections of large batches of samples can be realized, and on-site high flux rapid detections can be realized. Therefore, the kit, the colloidal gold test paper strips and the method provided by the invention play an important role in the detections of beta-lactam antibiotics.

The invention discloses a kit test method of beta-lactam antibiotics residue in milk, comprising the following steps: performing once activation to bacillus stearothermophilus, then culturing the activated bacillus stearothermophilus in a production culture medium at 50-65 DEG C for 24-36h while stirring in a rotation speed of 100-150rpm, centrifugalizing to collect bacteria mire, adding agarose bromcresol purple solution, mixing evenly to ensure the number of spore in each kit reach 1.00*10<7>-2.50*10<8>cfu, subpackaging the spore in porous reaction vessels at 60-70 DEG C, covering aluminum-plastic film, placing upside down, sealing, placing the vessels in aluminum-plastic packages and storing in dark place while keeping from wet. The kit has the advantage of easy operation, high sensibility, good repeatability, low cost and high throughput, can be stored at 4-8 DEG C for 12-18 months and can be used to test beta-lactam antibiotics residue in milk.

The invention provides feruloyl esterase and a preparing method and application thereof. A feruloyl esterase gene coming from a soil macro gene library have the nucleotide sequence and amino acid sequence shown in SEQ ID NO.1 and SEQ ID NO.2. The gene contains a tetrapeptide SXXK sequence motif which is rarely seen, and after the esterase gene is inserted into plasmid pET28a(+), the gene is transformed into escherichia coli BL21(DE3) to achieve heterogeneous expression. The molecular weight of purified recombinase (DLFae4) is 38.3 kDa. Besides, it is put forward for the first time that novel feruloyl esterase can hydrolyze penbritin, penicillin, cefazolin and other lactam antibiotics. As is shown by site-directed mutagenesis experiments, a catalysis triplet of DLFae4 is composed of serine(S11), histidine (H74) and aspartic acid (D302), and the mutation of any of serine (S11), histidine (H74) and aspartic acid (D302) can cause loss of the catalysis capability of DLFae4. DLFae4 has a high hydrolytic activity on methyl ferulate and has good heat stability. In the presence of cellulase, DLFae4 can obviously increase the amount of ferulic acid released from destarched wheat bran. Due to peculiar activities and enzymatic characteristics of novel feruloyl esterase, novel feruloyl esterase can be applied to feed, paper making, food, pharmacy and other fields.

This invention provides beta-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a beta-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.

The invention discloses an application of a macrolide compound or a salt thereof and a pharmaceutical composition containing the macrolide compound or the salt, and provides a pharmaceutical composition. The pharmaceutical composition comprises one or more of a macrolide compound as shown in a formula 1 in the specification, a macrolide compound as shown in a formula 1' in the specification and pharmaceutically acceptable salts thereof, and beta-lactam antibiotics. One or more of the macrolide compound as shown in the formula 1, the macrolide compound as shown in the formula 1' and pharmaceutically acceptable salts thereof disclosed by the invention has/have the effects of improving the effects of beta-lactam antibiotics and inhibiting methicillin-resistant staphylococcus aureus (MRSA); the macrolide compound is a novel synergist, is good in in-vitro synergism, is capable of relieving the drug resistance of the methicillin-resistant staphylococcus aureus (MRSA) on beta-lactam antibiotics, and is a medicine with good market development prospect.

The invention discloses an animal bifidobacterium and a composition thereof, and belongs to the technical field of microbe application. The preservation number of the animal bifidobacterium provided by the invention is CGMCC No.4521 and is preserved in General Microbiology Center of Chinese Culture Collection Committee in Beijing on December 29, 2010. The animal bifidobacterium provided by the invention has a symplastic growth effect on lactobacillus casei, streptococcus faecium and bacillus cereus and has tolerance on carbostyril, aminoglycoside and monocyclic beta-lactam antibiotics, and the animal bifidobacterium is suitable for use in food, drugs and/or health care products.

The invention relates to a preparation of and compound injection formed by ª‰-lactam antibiotics and it and its application, which belongs to chemical chemical tragacanth . Make intosodium salt and kali salt, combined with ª‰-lactam antibiotics thy are then changes into powder injection; which can intravenous injection or intravenous drip with ª‰-lactam antibiotics at the sametime. It can remarktably increase the square below the curve, prolong half life of blood elimination (t1/2ª‰) of antibiotics, and the period of medicine density of ª‰-lactam antibiotics in blood surpassing that of the corresponding germ MIC; it can also reduce abuse of antibiotics, avoid generation and development of bacterial strain tolerant to medicine, has good safety and curative effect, stable quality and convenient use.

The invention relates to a therapy of an infection with a drug resistant bacterium wherein a characteristic of multivalent phenol derivatives and/or extracts from “Tara” which enhance the activity of β-lactam antibiotics on the drug resistant bacteria is utilized. Specifically, the invention relates to an enhancer of β-lactam antibiotics comprising a multivalent phenol derivative or its pharmaceutically acceptable salt, a pharmaceutical composition comprising a β-lactam antibiotic and a multivalent phenol derivative and/or extract from “Tara” for the therapy of an infection with a drug resistant bacterium, a disinfectant for the same, and a functional food comprising a multivalent phenol derivative and/or extract from “Tara”.

The invention discloses macrolactone compounds or salts of the macrolactone compounds, as well as a synthesis method, a pharmaceutical composition and application of the macrolactone compounds or salts. The invention provides a macrolactone compound 1, a macrolactone compound 1' or salts of the macrolactone compound 1 and the macrolactone compound 1', a pharmaceutical composition containing the macrolactone compound 1, the macrolactone compound 1' or the salts of the macrolactone compound 1 and the macrolactone compound 1' and application of the pharmaceutical composition in preparing a drug for inhibiting methicillin-resistant staphylococcus aureus. When one or more of the macrolactone compound 1, the macrolactone compound 1', the salt of the macrolactone compound 1 and the salt of the macrolactone compound 1' are jointly used in combination with beta-lactam antibiotics, the inhibiting effect of the beta-lactam antibiotics on the methicillin-resistant staphylococcus aureus can be obviously increased. The macrolactone compounds and the salts thereof are novel synergists having good in-vitro synergistic effect, can alleviate the drug resistance of the methicillin-resistant staphylococcus aureus to the beta-lactam antibiotic and are drug having good market development prospects.

The invention belongs to the field of food detection and in particular relates to a kit for quantitatively detecting beta-lactamase residue in milk. The kit for quantitatively detecting beta-lactamase residue in milk is characterized in that the kit comprises an elisa plate enveloped with penicillin-binding proteins, marker coupled beta-lactam antibiotics, a skim milk powder freeze dried product of which the substrate reference 1 is beta-lactam antibiotics and which has the concentration of 0ppb, a skim milk powder freeze dried product of which the substrate reference 2 is beta-lactam antibiotics containing calibration concentration, and a beta-lactam antibiotic standard substance. The kit has high specificity and sensitivity, beta-lactam with the concentration of about 0.5U/ml can be detected, and the linear detection range is 1-16 U/ml; intra-batch CV percent of the kit is less than 10 percent, the inter-batch CV percent is less than 20 percent, and high precision is reflected; the detection steps are simple, the time consumption is low, and the cost is low; according to the kit, the beta-lactamase residue can be accurately, quantitatively and rapidly detected at high throughput, and the requirements of enterprises and detection mechanisms are met.

The invention relates to a selenium nano composite material capable of overcoming multi-drug-resistant bacterial infection. The selenium nano composite material comprises nano-selenium composite particles, which are obtained by coating mannose modified chitosan on the outer surface of a complex of selenium nano particles and beta-lactam antibiotics, and are of a spherical structure, wherein selenium nanoparticles and beta-lactam antibiotics are arranged in the nano-selenium composite particles, mannose-modified chitosan is arranged on the outer surface of the nano-selenium composite particles,the average particle size of the nano-selenium composite particles is 40-80 nm, and the thickness of shells of the mannose-modified chitosan on the surface is smaller than or equal to 5 nm. The invention also provides a selenium nano composite material capable of overcoming multi-drug-resistant bacterial infection, and application of the selenium nano composite material in a nano antibacterial material. The nano antibacterial material prepared by the invention inhibits the expression of a drug efflux pump of multi-drug-resistant bacteria and the activity of beta-lactamase, and chitosan is used for embedding selenium nanoparticles and antibiotics, so that the dispersity and stability of the nano material are favorably improved.

Disclosed are a DNA chip and a kit capable of quickly and accurately detecting or genotyping the highly prevalent and important eleven microbes causing sexually transmitted diseases (STD) Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, Mycoplasma hominis, syphilis-causing treponema, pallidum, chancroid-causing Haemophilus ducreyi, genital herpes-causing herpes simplex virus 1 and 2, human papillomavirus (HPV) and Trichomonas vaginalis and three related organisms Candida albicans, Gardnerella vaginalis and coliform bacteria and analyzing antibiotic resistance against tetracycline and lactam antibiotics, and a method for detecting or genotyping using the same. According to the present invention, the presence, genotype and antibiotic resistance of the fourteen organisms can be analyzed quickly and accurately from a DNA sample. With excellent sensitivity, specificity, reproducibility and accuracy of the 14 STD-causing and related microorganisms may be automatically identified quickly and accurately from multiple samples, and selection of antibiotics may be aided.

The invention discloses a method for detecting sulfonamide and beta-lactam antibiotics in livestock and poultry breeding wastewater. The method comprises the following steps: sequentially centrifugingand filtering a to-be-detected water sample; adding deionized water into the obtained filtrate for dilution; adding Na2EDTA, adjusting the pH, carrying out solid-phase extraction treatment on the obtained pre-treated water sample, carrying out negative-pressure leaching treatment and normal-pressure elution treatment on a solid-phase extraction column subjected to the solid-phase extraction treatment, collecting eluent, and then carrying out nitrogen blowing and constant volume treatment to obtain an antibiotic solution to be detected; and carrying out antibiotic content detection on the antibiotic solution to be detected by adopting a high performance liquid chromatography-tandem mass spectrometry method. According to the detection method disclosed by the invention, a solid phase extraction-liquid chromatography tandem mass spectrometry method is adopted, and various process conditions and parameters are selected and determined, so that the detection method can be used for rapidly and accurately detecting antibiotics in water and detecting sulfonamide and beta-lactam antibiotics in the livestock and poultry breeding wastewater at the same time.

The invention opened the peptides which can inhibit the ª‰ ¿Clactamases and the gene which can encode the peptides; also it provided the method to prepar the peptides by the expressing carrier. The gene is made up of the 72 nucleotides which encode the 24 amino acids whose mass is 2600Da. The peptides expressed in the E.Coli by the gene can inhibit the ª‰ ¿Clactamases. So it can cure the bacteria infection with the ª‰-lactam Antibiotics.